Vertex Pharmaceuticals (VRTX) Cash from Restructuring (2009 - 2017)
Vertex Pharmaceuticals' quarterly Cash from Restructuring came in at -$2.1 million in Q4 2017, down 392.97% year-on-year from $725000.0 in Q4 2016, and up 24.28% quarter-over-quarter from -$2.8 million in Q3 2017.
Vertex Pharmaceuticals has reported Cash from Restructuring for 9 years, with the latest figure at -$2.1 million in Q4 2017.
- For the quarter ending Q4 2017, Cash from Restructuring fell 392.97% year-over-year to -$2.1 million; the trailing twelve-month figure through Dec 2017 stood at -$6.0 million (up 19.38% YoY), and the FY2017 full-year result was -$6.0 million, up 19.38% from the prior year.
- Cash from Restructuring for Q4 2017 stood at -$2.1 million, up from -$2.8 million in the prior quarter.
- The five-year high for Cash from Restructuring was $36.6 million in Q3 2014, with the low at -$24.4 million in Q1 2015.
- Average Cash from Restructuring over 5 years is -$1.1 million, with a median of -$1.6 million recorded in 2015.
- Peak annual rise in Cash from Restructuring reached 796.18% in 2014, while the deepest fall reached 1099.75% in 2014.
- Tracing VRTX's Cash from Restructuring over 5 years: stood at $2.2 million in 2013, then plunged by 540.05% to -$9.7 million in 2014, then jumped by 74.96% to -$2.4 million in 2015, then jumped by 129.7% to $725000.0 in 2016, then tumbled by 392.97% to -$2.1 million in 2017.
- The last three Cash from Restructuring figures came in at -$2.1 million (Q4 2017), -$2.8 million (Q3 2017), and -$1.4 million (Q2 2017), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Revolution Medicines | 32.39 Bn | 32.39 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2017 | -2.12 Mn |
| Sep 30, 2017 | -2.81 Mn |
| Jun 30, 2017 | -1.36 Mn |
| Mar 31, 2017 | 305,000.00 |
| Dec 31, 2016 | 725,000.00 |
| Sep 30, 2016 | -5.26 Mn |
| Jun 30, 2016 | -1.43 Mn |
| Mar 31, 2016 | -1.46 Mn |
| Dec 31, 2015 | -2.44 Mn |
| Sep 30, 2015 | -2.04 Mn |
| Jun 30, 2015 | -1.65 Mn |
| Mar 31, 2015 | -24.37 Mn |
| Dec 31, 2014 | -9.75 Mn |
| Sep 30, 2014 | 36.62 Mn |
| Jun 30, 2014 | -4.88 Mn |
| Mar 31, 2014 | -4.49 Mn |
| Dec 31, 2013 | 2.22 Mn |
| Sep 30, 2013 | 4.09 Mn |
| Jun 30, 2013 | -407,000.00 |
| Mar 31, 2013 | -869,000.00 |
| Dec 31, 2012 | -827,000.00 |
| Sep 30, 2012 | -675,000.00 |
| Jun 30, 2012 | -643,000.00 |
| Mar 31, 2012 | -840,000.00 |
| Dec 31, 2011 | -271,000.00 |
| Sep 30, 2011 | -1.62 Mn |
| Mar 31, 2011 | -781,000.00 |
| Dec 31, 2010 | -3.64 Mn |
| Sep 30, 2010 | -686,000.00 |
| Jun 30, 2010 | 591,000.00 |
| Mar 31, 2010 | -684,000.00 |
| Dec 31, 2009 | 659,000.00 |
| Sep 30, 2009 | -692,000.00 |
| Jun 30, 2009 | -761,000.00 |
| Mar 31, 2009 | 747,000.00 |